chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My mom received her second covid shot at 10:05 AM on 3/26 and experienced no adverse symptoms. At around 6 am the following day, on the morning of 3/27 she was found on the floor, and presumably suffered from a heart attack. After devastation to our family, we called her physician and he himself was also surprised. Although she is a type 2 diabetic with high blood pressure she has maintained great health and kept her conditions under control with her medications. This, unfortunately, seems too coincidental to not have been in some way or completely caused by the second dose of the shot.
2nd injection got numbness; face got itchy; then got red raised bumps on legs; sore throat and ears, pain in chest.; sore throat and ears, pain in chest.; sore throat and ears, pain in chest.; This is a spontaneous report from a contactable consumer or other non health care professional. A 41-years-old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 16Apr2021 15:00 (Batch/Lot Number: EW0170) as 2ND DOSE, SINGLE for covid-19 immunisation. Medical history included asthma from an unknown date and unknown if ongoing. Concomitant medication included tizanidine (TIZANIDINE) taken for an unspecified indication, start and stop date were not reported. The patient experienced 2nd injection got numbness, face got itchy, then got red raised bumps on legs, sore throat and ears, pain in chest (non-serious) on unspecified date. The outcome of the events were recovered with sequelae.  No follow-up attempts are needed as information about lot/batch number obtained.
He experienced "a little pain" at the injection site/ "pain picked up"/ paint "went down"/ "got worse"; This spontaneous report has been received from a consumer, regarding to himself as a 41-year-old male patient. The patient's current conditions included migraine and drug hypersensitivity. His historical drugs included fluticasone propionate (FLONASE). Patient's concomitant therapies included loratadine (also reported as generic version of loratadine (CLARITIN)) and unspecified migraine medication. The patient's pertinent medical history was not reported.   On 05-JUL-2022, the patient was vaccinated with the third dose of HPV rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, in his left deltoid (also reported as shoulder) (strength, dosage, route of administration, vaccination scheme frequency, lot number, and expiration date were not reported) to prevent human papilloma virus (HPV) and future cancers. On unspecified dates, the patient received the first and second HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection, as prophylaxis (doses, routes of administration, anatomical sites of injection, lot numbers, and expiration dates were not reported).    On 05-JUL-2022, the patient experienced a little pain at the injection site (vaccination site pain). On 06-JUL-2022, he suffered a pain picked up. On 07-JL-2022, the paint went down, but after that paint just got worse. Also, when he lifted anything at all, he felt a "sharp jab" of pain at the injection site. In addition, the patient did not seek medical attention. At the time of the reporting, the patient had not recovered from vaccination site pain.   The causality assessment between the event and the suspect vaccine was not provided.
This form submitted upon the request of patient. Patient describes symptoms of right leg numbness, headache, back pain, light rash over entire body, generalized itching within 3 hours of vaccination. Rash resolved in one hour. Other symptoms have been intermittent for the last week. On 04/27 patient had wheezing. On 05/01 patient had cramps in both legs. These symptoms may represent a viral syndrome, but are not consistent with a known adverse event.
Large erythematous induration on anterior part of left thigh. Instructed patient to use ice compress.
Rash in Arm of the injection and lower leg; the rash is so itchy that she can not sleep; Lack of sleep; PAIN AT THE SITE OF INJECTION; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE RASH (Rash in Arm of the injection and lower leg), RASH PRURITIC (the rash is so itchy that she can not sleep), INSOMNIA (Lack of sleep) and INJECTION SITE PAIN (PAIN AT THE SITE OF INJECTION) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012A21A and 017B21A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy (Latex allergy).   On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5. On 08-Mar-2021, the patient experienced INJECTION SITE PAIN (PAIN AT THE SITE OF INJECTION). On 05-Apr-2021, the patient experienced INJECTION SITE RASH (Rash in Arm of the injection and lower leg), RASH PRURITIC (the rash is so itchy that she can not sleep) and INSOMNIA (Lack of sleep). At the time of the report, INJECTION SITE RASH (Rash in Arm of the injection and lower leg), RASH PRURITIC (the rash is so itchy that she can not sleep), INSOMNIA (Lack of sleep) and INJECTION SITE PAIN (PAIN AT THE SITE OF INJECTION) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient reported self administration of Benadryl and hydro-cortisol balm to try to alleviate the symptoms.; Reporter's Comments: Patient reported that preferred way of contact is telephone by a Spanish speaking agent.
Patient warned he had a history of vasovagal reactions. Approx 2 minutes after his dose he began to seem dizzy and complained of a "heaviness all over" and was having tremors. He appeared to be short of breath. His demand pacemaker kicked in during his reaction.  He received immediate attention and monitoring from on-site paramedics. His condition improved and he was able to ambulate to a stretcher prior to transport to Emergency Department.
Fever; Muscle aches; Fatigue; Rash/hives at injection site and on arms; Rash/hives at injection site and on arms; Rash/hives at injection site and on arms; Rash/hives at injection site and on arms; This is a spontaneous report from a contactable consumer (patient). This is the second of two reports. A 32-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: EW0168, expiration date was not reported), via an unspecified route of administration, administered in left arm on 19May2021 at 01:00 (at the age of 32-years-old) as dose 2, single for covid-19 immunization. The patient medical history included blood pressure high. Concomitant medications included ethinylestradiol, norgestimate (SPRINTEC), loratadine, pseudoephedrine sulfate (CLARITIN-D) both taken for unknown indications from an unknown date. The patient historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: EW0176, expiration date was not reported), via an unspecified route of administration, administered in left arm on 28Apr2021 at 14:45 (at the age of 32-years-old) as dose 1, single for covid-19 immunization and experienced rash/hives at injection site and on arms. The patient previously received vancomycin (MANUFACTURER UNKNOWN) for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021 the patient experienced rash/hives at injection site and on arms. On 20May2021 at 07:00, the patient experienced fever, muscle aches and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events rash/hives at injection site and on arms, fever, muscle aches and fatigue were recovered on an unknown date in May2021.  Follow-up attempts are completed. No further information is expected.
Caller stated that she received her second vaccine on 4/05/2021 and a few hours later she became lightheaded and dizzy. She fell down when at home and could not get up, she crawled to her bedroom and tried to get up and broke her right foot while trying to get up. She states that she had a reaction with the first one, but was not as severe as the second one. She state that she contacted her PCP.
Diarrhea, severe stomach pain, vomiting, fever escalating to 104 degrees that did not finally go away for 5 days, some numbness in legs, and some difficulty breathing.
The 12:20 pm appointment today (4/20/21) had an adverse reaction to the IMZ. Patient was done receiving the vaccine at about 12:30 pm and I stated she would have to wait until 12:45 pm. Around 12:38 pm I noticed she looked a little pale and went to her side to check on her. The patient stated she was feeling light-headed, dizzy, nauseous, and had trouble with her vision. I had the patient lay down and elevate her feet. The technician also grabbed an ice pack to place behind her neck. Asked if she would like water. The patient then stated she was having trouble breathing/short of breath and her ears were ringing. Once the patient stated issues with breathing 911 was called. A code white had been called and management was in the pharmacy. The 911 operator continued to ask questions about the patient's status and stated to not give any water or medications. I continued to assess the patient's symptoms. Her vision improved; however, she continued to feel light-headed, nauseous, and having trouble breathing. A member of EMS was in the store and came over to assess the patient. He had the patient sit up but she continued to have the same symptoms. He assessed her IMZ site. She was not feeling itchy and had not developed any hives. The ambulance arrived. EMS evaluated the patient and then took her out of the store on the stretcher.
mom states pt started w/fever same day of shots & fever was 104 p/lunch that day; called MD & was told to give APAP & fever came down, no c/o problems p/that;
This case was reported by a nurse via call center representative and described the occurrence of malaise in a adult patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced malaise and chills. On an unknown date, the outcome of the malaise and chills were unknown. It was unknown if the reporter considered the malaise and chills to be related to SHINGRIX. Additional details were provided as follows: The age at the vaccination was not reported. The age group was not reported but was selected as an adult as per vaccine indication. The reporter stated that, the patient experienced malaise and chills after receiving 1st dose of SHINGRIX. The events were not extreme allergic reaction but mild as described as malaise and chills. This case has been linked to case US2019GSK053162, reported by same reporter.
tiredness; headache; muscle pain; chills; un-controlled shaking; fever; nausea; loss of balance; ringing in the ears; This is a spontaneous report from a contactable consumer (patient). A 59-year-old male patient received first dose of BNT162B2 (PFIZER- BIONTECH COVID-19 VACCINE, solution for injection; Batch/Lot number was not reported), via an unspecified route of administration, administered on Arm Left on 24Mar2021 08:15 as dose 1, single for COVID-19 immunization at hospital. Medical history included prostate cancer. The patient had no known allergies to medications, food, or other products. Concomitant medications included Escitalopram at 10 mg; Pantoprazole 40 mg; Metoprolol Tartrate; all are received within four weeks of vaccination. The patient did not receive any other vaccines within four weeks. On 24Mar2021 19:30, the patient experienced tiredness, headache, muscle pain, chills, un-controlled shaking, fever (102 degrees), nausea, loss of balance and ringing in the ears. The patient did not have Covid prior vaccination and was not tested for Covid post vaccination. No treatment was received for the events. The outcome of events was recovered in Mar2021.    No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Date vials initially stored was 31-Jan-2022, Thaw expiration date: 02-Mar-2022, vaccine administered on 03-Mar-2022; Receiving doses after the beyond use date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Receiving doses after the beyond use date) and PRODUCT STORAGE ERROR (Date vials initially stored was 31-Jan-2022, Thaw expiration date: 02-Mar-2022, vaccine administered on 03-Mar-2022) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Mar-2022 at 8:19 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 03-Mar-2022 at 8:19 AM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Receiving doses after the beyond use date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Date vials initially stored was 31-Jan-2022, Thaw expiration date: 02-Mar-2022, vaccine administered on 03-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Receiving doses after the beyond use date) and PRODUCT STORAGE ERROR (Date vials initially stored was 31-Jan-2022, Thaw expiration date: 02-Mar-2022, vaccine administered on 03-Mar-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported.  It was reported that the vials were initially stored on 31-Jan-2022 and the thaw expiration date was 02-Mar-2022. It was also reported that the vial didn't undergo any temperature excursions.  The patient received their first booster dose.  No treatment information was provided.
On September 7, 2021 my husband spiked a fever of 100 and became confused. He is still in the early stages of dementia and he is forgetful never confused. His gait changed in the evening also and he was having trouble walking and seemed unbalanced over the next 2 days. He awoke on September 9th at 4 am and went to bathroom and then could not get up off the toilet. It took two people to stand him up and he could not move his legs or sustain a standing position. He was carried back to bed. The PCP was called and did not feel it was vaccine related. I was told if this continued then to call 911 and take him to the ED. He awoke 3 hours later with no fever, was coherent and though he had some difficulty standing and used a walker for balance, he was able to ambulate. With 48 hours he was able to ambulate independently and his cognitive was at baseline. I would have reported this earlier but since the PCP did not think this was related I did not report.  Earlier this morning I heard on the news, a physician speaking about  a few cases where patients had sudden onset of difficulty walking and inability to stand. I thought you would want to know that this was a reaction to vaccine which occurred with my husband.
Received the second dose out of the allowed window of time; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose out of the allowed window of time) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Feb-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose out of the allowed window of time). On 03-Feb-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received the second dose out of the allowed window of time) had resolved.            Concomitant medication was not reported. Treatment medication was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 25-Mar-2021: No new information; Sender's Comments: This report refers to a case of Inappropriate schedule of product administration for mRNA-1273, lot# 030L20A, with no associated adverse events.
A spontaneous report was received via email from a consumer on 31JAN2017. A husband reported that his wife, went from a healthy vibrant person to sick patient that spends most of her time seeing doctors who can't tell what is wrong exactly. He reports that she started showing signs of autoimmune disease following her anthrax vaccine administered. The husband stated that his wife went from being a fitness leader to being bedridden at 35 years old. She was medically discharged after serving 16 years. Additional information has been requested.
Injection of PNEUMOVAX. Soreness for three days and counting, extreme fatigue, irritability, muscle aches.
Pt came to our clinic requesting HPV vaccine. Risks benefits described. Consent forms signed. By day after receiving HPV9 #1, she felt a dull ache in her deltoid at the injection site. She called our office today 8/6/2020 to report. no fevers, no redness, no swelling. no loss of strength. No sensation changes. Reports dull ache has not improved over 3 weeks and worsens if she rolls on it in sleep or moves or palpates deltoid.  Told her probably prolonged inflammatory response in muscle, perhaps with nerve irritation. Told her to try motrim or tylenol and resting deltoid. Told her we were cancelling her #2 and #3 shots since her risk benefit calculus had shifted for an elective vaccine, and recommended other ways to limit/prevent HPV.
Neuropathy; pain at the injection site; pain at the injection site on the right arm and goes to the right hip; This case was reported by a physician via call center representative and described the occurrence of neuropathy in a 56-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th January 2020, the patient received the 1st dose of Shingrix. On an unknown date, less than 4 months after receiving Shingrix, the patient experienced neuropathy (serious criteria GSK medically significant), injection site pain and pain in hip. On an unknown date, the outcome of the neuropathy, injection site pain and pain in hip were recovering/resolving.   It was unknown if the reporter considered the neuropathy, injection site pain and pain in hip to be related to Shingrix.  Additional information was received as follows: The patient received Shingrix on her right arm. The patient received Shingrix and had pain at the injection site on the right arm and goes to the right hip, also developed a neuropathy and had not recovered. The reporter consented to follow up.
Woke up on 01/10/2021 with tender left breast, under the breast was red and hard.  Had to have area drained and packed
3 patients received vaccine from vial opened more than 12 hours ago; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (3 patients received vaccine from vial opened more than 12 hours ago) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 058H21A and 031A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Dec-2021 at 4:20 PM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Dec-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (3 patients received vaccine from vial opened more than 12 hours ago). On 15-Dec-2021, EXPIRED PRODUCT ADMINISTERED (3 patients received vaccine from vial opened more than 12 hours ago) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication were provided.  It was reported that 3 patients came in for the Moderna COVID -19 vaccine and were administered vaccine from a Moderna Covid-19 vial that had been left out at room temperature and was punctured on 14-Dec-2021. The vial was stored post puncture in room temperature. The vial did not  undergo any temperature excursions. No other adverse reactions were reported.   This case was linked to MOD-2022-459148, MOD-2022-459165 (Patient Link).
Pt received 1st dose of Pfizer dose. Allergies to iodine. Pt started exhibiting difficulty swallowing. Pt was able to talk. BP 172/97. HR 78. SaO2 99%.   Paramedics stayed with pt for 20 minutes until pt said the feeling had passed and she was able to drive home.  Zero reports of difficulty breathing, no drop in SaO2
We accidentally gave a bivalent Pfizer booster as a first dose in a vaccine series.  I contacted the CDC, and we will continue with the second monovalent dose in the series.
Super sick after the 2nd dose; The allergies are no longer like before.; Glands under the throat are bothering them as they were inflamed/lymph nodes are activated; Getting tired more than usual; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Super sick after the 2nd dose), THERAPEUTIC RESPONSE UNEXPECTED (The allergies are no longer like before.), LYMPHADENITIS (Glands under the throat are bothering them as they were inflamed/lymph nodes are activated) and FATIGUE (Getting tired more than usual) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy (Every year, starts around April.).    In 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Super sick after the 2nd dose), THERAPEUTIC RESPONSE UNEXPECTED (The allergies are no longer like before.), LYMPHADENITIS (Glands under the throat are bothering them as they were inflamed/lymph nodes are activated) and FATIGUE (Getting tired more than usual). At the time of the report, ILLNESS (Super sick after the 2nd dose), THERAPEUTIC RESPONSE UNEXPECTED (The allergies are no longer like before.), LYMPHADENITIS (Glands under the throat are bothering them as they were inflamed/lymph nodes are activated) and FATIGUE (Getting tired more than usual) outcome was unknown.      The patient had allergies every year and patient went to the doctor to get treatment for their allergies but their symptoms got worse every year. No concomitant medications were provided. The patient went to the doctor or urgent care clinic because they were getting tired more than usual. Patient was prescribed with antibiotics as a treatment.   Reporter did not allow further contact
Day 1.  Two small twinges in left upper chest area  while sitting in holding area.  Upper left arm pain, various aches and pain in back and upper left thigh.  Tiredness similar to what I had with Covid in November.  Day 2 Temperature went up to 99.4 just prior to bed.  Lethargic feeling  and continued pain in arm and aches in body.  Day 3.  Nothing appearing right now
Difficulty breathing, Sweaty, Back/Abdominal pain 142/99; 100, 24, O2 sat99 Transferred to ER, released 4 hours later